8-K: Achieve Life Sciences Reports Q1 2024 Financial Results and Provides Corporate Update

Achieve Life Sciences announced its first quarter 2024 financial results, highlighted by a $60 million capital raise and progress in cytisinicline development.

Summary

• Achieve Life Sciences reported a net loss of $6.5 million for the first quarter of 2024.
• The company's operating expenses totaled $6.0 million for the quarter.
• As of March 31, 2024, Achieve had $66.4 million in cash, cash equivalents, and restricted cash.
• A recent equity financing secured up to $124.2 million, including $60.0 million upfront and up to an additional $64.2 million upon exercise of milestone-driven warrants.
• The company plans to initiate the ORCA-OL trial in May 2024 to evaluate the long-term safety of cytisinicline.
• The New Drug Application (NDA) submission for cytisinicline is anticipated in the first half of 2025.
• Phase 2 ORCA-V1 trial results, showing cytisinicline more than doubled the odds of achieving vaping abstinence, were published in JAMA Internal Medicine.
• Clinical data from Phase 3 ORCA-2 and ORCA-3 trials, and Phase 2 ORCA-V1 trial were presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting.
• Survey results from Phase 3 participants revealed that 69% of those who received cytisinicline experienced success in quitting smoking and 22% experienced a significant reduction in smoking.

Sentiment

Score: 8

Explanation: The document is positive due to the successful capital raise, progress in clinical trials, and publication of positive results. The company is on track with its development plans and has sufficient funding to reach key milestones. The only negative is the net loss, which is expected for a company at this stage.

Positives

• The company successfully raised $60 million in upfront funding, with potential for an additional $64.2 million.
• The ORCA-OL trial is on track to start in May 2024, which is a key step towards NDA submission.
• The publication of the ORCA-V1 trial results in JAMA Internal Medicine highlights the credibility of the research.
• Clinical data presented at the SRNT conference showed positive results for cytisinicline in both smoking and vaping cessation.
• The company has sufficient funding to support the development of cytisinicline into 2026 and through potential FDA approval.

Negatives

• The company reported a net loss of $6.5 million for the first quarter of 2024.
• Operating expenses were $6.0 million for the quarter.

Risks

• The company's success is dependent on the successful development and regulatory approval of cytisinicline.
• There is a risk that cytisinicline may not demonstrate the expected benefits.
• The company may need to secure additional financing in the future.
• There are risks related to the impact of macroeconomic and geopolitical environment, including inflation, increased volatility in interest rates and the debt and equity markets, instability in the global banking system, global health crises and pandemics and geopolitical conflict.

Future Outlook

Achieve expects proceeds from the recent financing, plus existing cash, will be sufficient to fund its development of cytisinicline into 2026 and through potential FDA approval. The company anticipates submitting an NDA in the first half of 2025.

Management Comments

• We are pleased with the progress we've made on preparations for the ORCA-OL trial, which we expect to initiate in the coming weeks, stated John Bencich, Chief Executive Officer of Achieve.
• We are also pleased to once again this quarter have our trial results presented and published in highly esteemed medical forums, demonstrating the quality and standard of excellence of our clinical development program.

Industry Context

The announcement is relevant to the pharmaceutical industry, particularly companies focused on smoking cessation and nicotine addiction treatments. The company is addressing a significant market need, given the high prevalence of smoking and vaping and the lack of FDA-approved treatments for e-cigarette cessation.

Comparison to Industry Standards

• The publication of the ORCA-V1 trial results in JAMA Internal Medicine is a significant achievement, as it demonstrates the scientific rigor of the company's research, which is comparable to other leading pharmaceutical companies.
• The reported success rates of 69% for quitting smoking and 22% for significant reduction in smoking among cytisinicline users in Phase 3 trials are competitive with other smoking cessation treatments.
• The company's focus on both smoking and vaping cessation positions it well in the market, as there are currently no FDA-approved treatments specifically for e-cigarette cessation, giving them a potential first mover advantage.
• The $124.2 million capital raise is a substantial amount for a company of this size, indicating strong investor confidence in the potential of cytisinicline, which is comparable to other companies in the biotech space.

Stakeholder Impact

• Shareholders will benefit from the company's progress in clinical trials and the potential for FDA approval of cytisinicline.
• Employees will continue to be involved in the development and commercialization of cytisinicline.
• Customers (smokers and vapers) may have a new treatment option for nicotine addiction.
• Creditors are likely to be reassured by the company's strong cash position and funding.

Next Steps

• Initiate the ORCA-OL trial in May 2024.
• Conduct an end-of-Phase 2 meeting with the FDA to discuss plans for an expanded label in e-cigarette cessation.
• Submit a New Drug Application (NDA) in the first half of 2025.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine addiction, vaping cessation, clinical trials, NDA submission, ORCA-OL, ORCA-V1, ORCA-2, ORCA-3, FDA, pharmaceutical, equity financing